Merit Medical(MMSI) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported total revenue of $393.9 million for Q4 2025, representing an 11% year-over-year increase on a GAAP basis and a 10% increase on a constant currency basis [6][7] - Non-GAAP operating margin increased by 138 basis points year-over-year to 21% [7][18] - Non-GAAP EPS grew by 12% year-over-year, exceeding expectations [8] - Free cash flow for Q4 was $74 million, up 13% year-over-year, marking a quarterly record for the company [8][19] - For the full year 2025, the company achieved constant currency revenue growth of 11% and generated nearly $216 million in free cash flow, up 16% year-over-year [19][20] Business Line Data and Key Metrics Changes - Q4 total revenue growth was driven by a 9% increase in the cardiovascular segment and a 15% increase in the endoscopy segment [10] - Cardiac Intervention product sales increased by 21%, with organic growth driven by strong sales in EP, CRM, angiography, and access products [11][12] - Peripheral Intervention products sales increased by 13%, primarily driven by strong sales in Radar Localization and delivery systems [13] - Sales of custom procedural solutions products increased by 4%, while OEM products sales decreased by 15% [14][15] Market Data and Key Metrics Changes - U.S. sales increased by 12% year-over-year, while international sales increased by 6% [16] - U.S. organic constant currency sales growth was 8%, and international organic constant currency sales growth was 4% [16] Company Strategy and Development Direction - The company aims to drive strong execution globally and successfully complete its Continued Growth Initiatives program, targeting a 5%-7% organic constant currency revenue CAGR for the three-year period ending December 31, 2026 [9][37] - The divestiture of the DualCap product line is expected to create additional manufacturing capacity and free up resources for higher-margin products [24][38] - The company is focused on both internal product innovation and strategic M&A to enhance its competitive position [36][59] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the dynamic global macro environment but expressed confidence in the company's strong execution and commitment to financial targets [9][19] - The company expects solid constant currency growth and non-GAAP operating margin expansion in 2026, despite potential headwinds from tariffs and trade policies [22][25] Other Important Information - The company introduced financial guidance for 2026, projecting total GAAP net revenue growth of 6%-8% year-over-year and free cash flow of at least $200 million [22][27] - The expected impact of tariffs on non-GAAP EPS for 2026 is approximately $0.19 per share [25][26] Q&A Session Summary Question: What are the additional gross margin drivers for the company? - Management emphasized the importance of mix, pricing, cost discipline, and SKU rationalization to drive gross margin improvements [42][44] Question: How is the WRAPSODY product performing in the outpatient setting? - Management acknowledged that initial revenue expectations for WRAPSODY were missed but expressed confidence in achieving the $7 million revenue target for 2026 [46][48] Question: What factors are influencing the guidance for free cash flow in 2026? - Management indicated that the guidance reflects a conservative approach due to timing-based factors and ongoing capital expenditures [52][54] Question: What areas is the company looking at for potential M&A? - The company is focusing on both foundational and therapeutic products, seeking strategic opportunities that align with its growth drivers [56][59] Question: What is the outlook for the OEM business? - Management noted that the OEM business is expected to normalize to mid-to-high single-digit growth, despite recent inventory destocking [62][63]